Quintet Private Bank Europe S.A. Increases Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Quintet Private Bank Europe S.A. lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 97,241 shares of the medical research company’s stock after purchasing an additional 480 shares during the quarter. Thermo Fisher Scientific comprises about 3.2% of Quintet Private Bank Europe S.A.’s holdings, making the stock its 11th biggest holding. Quintet Private Bank Europe S.A.’s holdings in Thermo Fisher Scientific were worth $51,615,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Syon Capital LLC lifted its position in Thermo Fisher Scientific by 59.0% in the fourth quarter. Syon Capital LLC now owns 3,350 shares of the medical research company’s stock valued at $1,778,000 after buying an additional 1,243 shares during the last quarter. Centaurus Financial Inc. lifted its position in Thermo Fisher Scientific by 10.1% in the fourth quarter. Centaurus Financial Inc. now owns 5,931 shares of the medical research company’s stock valued at $3,148,000 after buying an additional 546 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $295,000. Teachers Retirement System of The State of Kentucky lifted its position in shares of Thermo Fisher Scientific by 67.3% during the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 90,202 shares of the medical research company’s stock worth $47,879,000 after purchasing an additional 36,276 shares in the last quarter. Finally, Sierra Summit Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $7,121,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $567.28, for a total value of $5,672,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $70,238,340.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $567.28, for a total value of $5,672,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $70,238,340.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the transaction, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. Over the last quarter, insiders sold 22,000 shares of company stock valued at $12,532,780. 0.34% of the stock is owned by company insiders.

Analyst Ratings Changes

TMO has been the topic of several research reports. Robert W. Baird reduced their price target on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a research report on Thursday, April 25th. Barclays upped their target price on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 25th. Jefferies Financial Group restated a “buy” rating and set a $650.00 target price (up from $600.00) on shares of Thermo Fisher Scientific in a research note on Monday, June 3rd. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a research note on Monday, March 18th. They set a “neutral” rating and a $620.00 target price on the stock. Finally, Evercore ISI upped their target price on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Five investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $607.94.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO traded down $0.19 during mid-day trading on Friday, hitting $572.05. 1,413,701 shares of the company were exchanged, compared to its average volume of 1,222,423. The company has a quick ratio of 1.33, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. The stock has a 50 day simple moving average of $575.16 and a 200-day simple moving average of $558.36. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The firm has a market cap of $218.36 billion, a price-to-earnings ratio of 36.69, a price-to-earnings-growth ratio of 2.67 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The company had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Shareholders of record on Friday, June 14th will be issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date of this dividend is Friday, June 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.